Skip to main content

Table 6 Treatment-related toxicities after each cycle of topotecan and cyclophosphamide containing induction therapy

From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

  Data First cycle Second cycle
Hospital stay (days) Median (range) 7 (5–10) 5 (5–40)
Nadir period (days) Median (range) 15 (10–20) 15 (10–20)
Readmission after chemotherapy No 71 (66.4) 88 (82.2)
Ward 33 (30.8) 18 (16.8)
ICU 3 (2.8) 1 (0.9)
Febrile neutropenia No 63 (58.9) 86 (80.4)
Yes 44 (41.1) 21 (19.6)
Mucositis No 84 (78.5) 93 (86.9)
Yes 23 (21.5) 14 (13.1)
Diarrhea No 102 (95.3) 103 (96.3)
Yes 5 (4.7) 4 (3.7)
Typhlitis No 106 (99.1) 106 (99.1)
Yes 1 (0.9) 1 (0.9)
Renal dysfunction No 106 (99.1) 106 (99.1)
Yes 1 (0.9) 1 (0.9)
Elevated liver enzymes No 105 (98.1) 106 (99.1)
Yes 2 (1.9) 1 (0.9)
  1. Notes: Data are presented as number (%) for categorical variables
\